Atria Wealth Solutions Inc. Has $4.42 Million Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Key Points

• Atria Wealth Solutions Inc. increased its stake in Becton, Dickinson and Company by 81.2%, owning 19,303 shares valued at approximately $4.42 million as of the latest SEC filing.
• Institutional investors collectively hold 86.97% of Becton, Dickinson and Company's stock, with notable increases from T. Rowe Price and Kovitz Investment Group in the past quarters.
• Becton, Dickinson and Company's stock has seen a 10.4% year-over-year revenue increase, reporting $5.51 billion in revenue for the latest quarter and exceeding earnings estimates.

Atria Wealth Solutions Inc. grew its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 81.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 19,303 shares of the medical instruments supplier's stock after purchasing an additional 8,650 shares during the quarter. Atria Wealth Solutions Inc.'s holdings in Becton, Dickinson and Company were worth $4,421,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Northcape Wealth Management LLC boosted its stake in Becton, Dickinson and Company by 0.5% during the 1st quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier's stock valued at $2,248,000 after purchasing an additional 51 shares in the last quarter. Alpha Omega Wealth Management LLC grew its stake in shares of Becton, Dickinson and Company by 5.7% in the 1st quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier's stock valued at $225,000 after purchasing an additional 53 shares during the period. Brady Family Wealth LLC grew its stake in shares of Becton, Dickinson and Company by 1.2% in the 1st quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier's stock valued at $989,000 after purchasing an additional 53 shares during the period. Diversified Trust Co grew its stake in shares of Becton, Dickinson and Company by 4.7% in the 1st quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier's stock valued at $272,000 after purchasing an additional 53 shares during the period. Finally, REAP Financial Group LLC boosted its holdings in shares of Becton, Dickinson and Company by 75.3% in the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after acquiring an additional 55 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.

Analyst Upgrades and Downgrades

BDX has been the topic of several recent research reports. Raymond James Financial cut Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a report on Friday, May 2nd. Wall Street Zen upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday. Piper Sandler reaffirmed a "neutral" rating and set a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday. Bank of America downgraded Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 target price for the company. in a research note on Thursday, May 1st. Finally, The Goldman Sachs Group cut shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 target price on the stock. in a research report on Friday, May 2nd. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $211.44.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock traded up $0.62 during trading hours on Tuesday, hitting $193.12. The company's stock had a trading volume of 995,773 shares, compared to its average volume of 2,665,209. The company has a 50 day moving average of $176.28 and a 200 day moving average of $198.06. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The stock has a market cap of $55.35 billion, a PE ratio of 34.74, a price-to-earnings-growth ratio of 1.46 and a beta of 0.20. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.28. The firm had revenue of $5.51 billion during the quarter, compared to analysts' expectations of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. Becton, Dickinson and Company's revenue was up 10.4% compared to the same quarter last year. During the same period last year, the business earned $3.50 earnings per share. On average, sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be issued a $1.04 dividend. The ex-dividend date of this dividend is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio (DPR) is 74.82%.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,185 shares of the firm's stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the sale, the executive vice president owned 4,887 shares in the company, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP David Shan sold 1,166 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the sale, the executive vice president directly owned 4,575 shares in the company, valued at $783,194.25. This represents a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 3,214 shares of company stock valued at $579,206. Corporate insiders own 0.36% of the company's stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.